Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | CTSL | P07711 | 3/20 | 0.49 |
| ▸ | MGLL | Q99685 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.46 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1219647 | 0.90 | MEN1 (0.53) | SMN1; SMN2NPC1RAB9ATP53MEN1 | |
| SCHEMBL1219646 | 0.90 | MEN1 (0.53) | SMN1; SMN2NPC1RAB9ATP53MEN1 | |
| SCHEMBL1221478 | 0.85 | ITGA4 (0.60) | SMN1; SMN2NPC1RAB9ATP53MEN1 | |
| SCHEMBL1221477 | 0.85 | ITGA4 (0.60) | SMN1; SMN2NPC1RAB9ATP53MEN1 | |
| SCHEMBL29069436 | 0.85 | RAB9A (0.49) | SMN1; SMN2NPC1RAB9ATP53MEN1 | |
| SCHEMBL28876338 | 0.85 | RAB9A (0.49) | SMN1; SMN2NPC1RAB9ATP53MEN1 | |
| SCHEMBL7315204 | 0.83 | MEN1 (0.54) | SMN1; SMN2NPC1RAB9ATP53MEN1 | |
| SCHEMBL1715173 | 0.83 | MEN1 (0.54) | SMN1; SMN2NPC1RAB9ATP53MEN1 | |
| SCHEMBL2747164 | 0.83 | KDM4A (0.57) | MAPTPPARG | |
| SCHEMBL3404531 | 0.83 | MEN1 (0.53) | SMN1; SMN2NPC1RAB9ATP53MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230144653-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling Pathways | AURIGENE ONCOLOGY LIMITED (IN) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230144653-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling Pathways | CD47, HIF1AN, PIK3R5 | SMN1; SMN2 2273/4885NPC1 1986/4885RAB9A 1523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.